QuidelOrtho Corporation (QDEL) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
QuidelOrtho Corporation (QDEL) slipped -1.78% to $13.76, trading at 15% of its 52-week range ($9.92 – $35.58). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to make lab operations smoot
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will issue a press release to report its financial results for the third quarter 2026 end
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on QDEL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for QDEL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, QuidelOrtho Corporation (QDEL) ranks #940 by composite RQD confidence (30/100, grade E) and #367 by equity capitalization ($943.6M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with QDEL at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QDEL
ACTIVE
QuidelOrtho Corporation | E | 30/100 | — | — | -35.0% | -1.78% | $943.6M | Benchmark Subject |
| ACHV Achieve Life Sciences Inc. | D | 44/100 | — | — | -35.0% | +4.96% | $739.9M | /achv-vs-qdel → |
| MYGN Myriad Genetics Inc. | D- | 39/100 | — | 69.9% | -35.0% | +0.60% | $638.0M | /mygn-vs-qdel → |
| NNNN Anbio Biotechnology (Class A) | D | 45/100 | 83.6x | 87.2% | 17.0% | -3.12% | $535.3M | /nnnn-vs-qdel → |
| TKNO Alpha Teknova Inc. | D | 44/100 | — | 33.2% | -21.3% | +2.93% | $499.2M | /tkno-vs-qdel → |
In its most recent audited fiscal period (FY2025, filed 2025-12-28), QuidelOrtho Corporation (QDEL) reported GAAP revenue of $2.73B (-1.9% vs. FY2024 revenue of $2.78B , and -8.9% cumulative change since FY2023) , GAAP net income of -$1.13B, operating cash flow of $105.2M, and free cash flow of -$83.0M (+26.0% YoY). On the balance sheet, QDEL closed FY2025 with $5.77B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-28 | $2.73B | -$1.13B | $105.2M | -$83.0M | $5.77B | — |
| FY2024 (FY) | 2024-12-29 | $2.78B | -$2.05B | $83.0M | -$112.1M | $6.42B | — |
| FY2023 (FY) | 2023-12-31 | $3.00B | -$10.1M | $280.2M | $280.2M | — | — |
As of 2026-11-01, QuidelOrtho Corporation (NASDAQ: QDEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $13.76 (-1.78% 1D, market cap $943.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QDEL ranks #940 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), QDEL carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $739.9M) and MYGN (Myriad Genetics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $638.0M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
Per QDEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0001906324), QuidelOrtho Corporation generated $2.73B in revenue (-1.9% YoY), -$1.13B in net income, and -$83.0M in free cash flow against $5.77B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
QDEL last traded at $13.76 (-1.78% on volume of 1,509,036 shares), positioning the stock +7.84% above its 50-day simple moving average ($12.76) and -15.38% below its 200-day simple moving average ($16.26). Across its 52-week range of $9.92 to $35.58, QDEL sits at the 15.0% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.04 to $15.48).
Why QDEL Stock slipped -1.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.